A total of 8032 (22.9%) patients had switched GLP-1 receptor agonist, with the most common drug switch being from liraglutide to semaglutide ( n = 5839
NICE has approved semaglutide (TA875) and liraglutide (TA664) for managing overweight and obesity in specific patient groups within specialist services, subject to prescribing criteria and monitoring requirements
Comparisons Of Cardiovascular Outcomes Among Oral Semaglutide And Other Injectable GLP-1RAs Whilst most of injectable GLP-1RA showed superiority to placebo for primary composite vascular outcome, as detailed earlier, oral semaglutide (PIONEER-6) confirmed only non-inferiority to placebo
Do not take Contrave if you: Have uncontrolled high blood pressure Have seizures or a history of seizures Have end-stage renal disease Take other medications that contain bupropion Have an eating disorder or history of eating disorders (such as anorexia or bulimia) Take opioid-containing medicines or use medications to help you stop taking opioid pain medicines Drink a lot of alcohol and then stop drinking Take sleeping medicine, anxiety medicine, or anti-seizure medicine and stop taking it suddenly Are taking a monoamine oxidase inhibitor (MAOI) medicine Are allergic to naltrexone, bupropion, or any ingredient in Contrave Before taking Contrave, tell your healthcare provider about any medical conditions you have, including heart disease, mental illnesses, head injury, kidney or liver problems, diabetes mellitus, or others
[DOI] [PubMed] [Google Scholar] 117.Su H., Liu H.Y., Pappa A.M., Hidalgo T.C., Cavassin P., Inal S., Owens R.M., Daniel S
